STOUGHTON, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that its management will participate in the following investor conferences:
2025 Wells Fargo Healthcare Conference
Thursday, September 4, 2025
Boston, MA
Morgan Stanley 23rd Annual Global Healthcare Conference
Fireside Chat Date and Time: Monday, September 8, 2025 at 2:35 p.m. ET
New York, NY
A live webcast of the fireside chat will be available via the Investors section of the Company's website: https://ir.collegiumpharma.com. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.
H.C. Wainwright 27th Annual Global Investment Conference
Fireside Chat Date and Time: Tuesday, September 9, 2025 at 10:30 a.m. ET
New York, NY
A live webcast of the fireside chat will be available via the Investors section of the Company's website: https://ir.collegiumpharma.com. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.
About Collegium Pharmaceutical, Inc.
Collegium is building a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The Company has a leading portfolio of responsible pain management medications and a rapidly growing neuropsychiatry business driven by Jornay PM®, a differentiated treatment for ADHD. Collegium’s strategy includes growing its commercial portfolio, with Jornay PM as the lead growth driver, and deploying capital in a disciplined manner. Collegium’s headquarters are located in Stoughton, Massachusetts. For more information, please visit the Company’s website at www.collegiumpharma.com.
Investor Contacts:
Ian Karp
Head of Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.
Danielle Jesse
Director, Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
Cheryl Wheeler
Head of Corporate Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$39.16 |
| Daily Change: | 0.36 0.93 |
| Daily Volume: | 482,844 |
| Market Cap: | US$1.230B |
August 25, 2025 August 07, 2025 May 08, 2025 March 27, 2025 March 17, 2025 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
